CT引导徒手腔内联合插植自适应后装与传统A点后装治疗宫颈癌剂量比较

doi:10.3760/cma.j.cn113030-20190312-00083

Abstract
Figure/Table
References(20)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To analyze the dosimetric differences between CT-guided free-hand intracavity/interstitial brachytherapy[image-guided adaptive brachytherapy (IGABT)] and conventional point-A plan (CP) in the treatment of cervical cancer. Methods Twenty-six cervical cancer patients who received four cycles of IGABT in Sun Yat-sen University Cancer Center were enrolled in this study. Two sets of CT images were obtained before and after applicator adjustment to aid in the design of CP and IGABT plans. The high-risk clinical target volume (HRCTV), point A, and organs at risk (bladder, rectum, and sigmoid colon) were defined on CT images. CP and IGABT plans were designed on CT images. Parameter differences between CP and IGABT plans were analyzed with paired t-test and Wilcoxon test. Results According to the coverage index (CI) of CP, plans were divided into two groups:in group A (CI≥0.90), 20 CP and corresponding IGABT plans were included, and 84 CP and corresponding IGABT plans in group B (CI<0.90). The mean volume of HRCTV and mean tumor diameter in group A were significantly smaller than those in group B (46.7 cm³ vs. 62.1 cm³, P<0.001 and 3.1 cm vs. 4.4 cm, P<0.001). Compared with CP, IGABT significantly improved the value of D90% in all plans and group B, whereas lowered the bladder dose. IGABT also reduced the dose of sigmoid colon in group A. IGABT significantly improved conformal index and dose homogeneity index. Conclusions IGABT can significantly improve the target coverage, conformal index and dose homogeneity index, protect organs at risk. Compared with CP, IGABT has advantages in the treatment of patients with bulky tumor.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Yanhong
	Ye Weijun
	Zhan Shizhao
	Ouyang Yi
	Cao Xinping

Key words： Cervical neoplasm/CT-guided free-hand intracavitary plus interstitial brachytherapy Cervical neoplasm/conventional point-A brachytherapy Dosimetry

Received: 12 March 2019

Corresponding Authors: Cao Xinping, Email:caoxp@sysucc.org.cn

Cite this article:

Wang Yanhong,Ye Weijun,Zhan Shizhao et al. Dosimetric comparison between CT-guided free-hand intracavity/interstitial adaptive brachytherapy and conventional point-A brachytherapy in the treatment of cervical cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 882-887.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190312-00083 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I10/882

[1] Toita T, Moromizato H, Ogawa K, et al. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer[J]. Gynecol Oncol, 2005, 96(3):665-670. DOI:10.1016/j.ygyno.2004.11.046.
[2] Murakami N, Kasamatsu T, Wakita A, et al. CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer[J]. BMC Cancer, 2014, 14:447. DOI:10.1186/1471-2407-14-447.
[3] WanderåsAD, Sundset M, Langdal I, et al. Adaptive brachytherapy of cervical cancer, comparison of conventional point A and CT based individual treatment planning[J]. Acta Oncol, 2012, 51(3):345-354. DOI:10.3109/0284186x.2011.626446.
[4] Onal C, Arslan G, Topkan E, et al. Comparison of conventional and CT-based planning for intracavitary brachytherapy for cervical cancer:target volume coverage and organs at risk doses[J]. J Exp Clin Cancer Res, 2009, 28(1):95. DOI:10.1186/1756-9966-28-95.
[5] Shin KH, Kim TH, Cho JK, et al. CT-guided intracavitary radiotherapy for cervical cancer:Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters[J]. Int J Radiat Oncol Biol Phys, 2006, 64(1):197-204. DOI:10.1016/j.ijrobp.2005.06.015.
[6] Tanderup K, Nielsen SK, Nyvang GB, et al. From point A to the sculpted pear:MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer[J]. Radiother Oncol, 2010, 94(2):173-180. DOI:10.1016/j.radonc.2010.01.001.
[7] Malyapa RS, Mutic S, Low DA, et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer[J]. Int J Radiat Oncol Biol Phys,2002, 54(4):1140-1146. DOI:10.1016/s0360-3016(02)03043-2.
[8] Nomden CN, de Leeuw AA, Moerland MA, et al. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 82(4):1424-1430. DOI:10.1016/j.ijrobp.2011.04.044.
[9] Dimopoulos JC, Kirisits C, Petric P, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:clinical feasibility and preliminary results[J]. Int J Radiat Oncol Biol Phys, 2006, 66(1):83-90. DOI:10.1016/j.ijrobp.2006.04.041.
[10] Wang Y, Ye WJ, Du LH, et al. Dose-volume parameters and clinical outcome of CT-guided free-hand high-dose-rate interstitial brachytherapy for cervical cancer[J]. Chin J Cancer, 2012, 31(12):598-604. DOI:10.5732/cjc.011.10452.
[11] Nag S, Cardenes H, Chang S, et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma:report from Image-Guided Brachytherapy Working Group[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1160-1172. DOI:10.1016/j.ijrobp.2004.04.032.
[12] Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC-ESTRO Working Group (I):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3):235-245. DOI:10.1016/j.radonc.2004.12.015.
[13] Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (Ⅱ):concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology[J]. Radiother Oncol, 2006, 78(1):67-77. DOI:10.1016/j.radonc.2005.11.014.
[14] Jacob D, Raben A, Sarkar A, et al. Anatomy-based inverse planning simulated annealing optimization in high-dose-rate prostate brachytherapy:significant dosimetric advantage over other optimization techniques[J]. Int J Radiat Oncol Biol Phys, 2008, 72(3):820-827. DOI:10.1016/j.ijrobp.2008.02.009.
[15] Huckle A, Al-Qaisieh B, Bownes P. Methods of verifying the output of the treatment planning system used for high dose rate (HDR) prostate brachytherapy[J]. Radiother Oncol, 2012, 103(2):261-265. DOI:10.1016/j.radonc.2011.09.022.
[16] Jamema SV, Sharma S, Mahantshetty U, et al. Comparison of IPSA with dose-point optimization and manual optimization for interstitial template brachytherapy for gynecologic cancers[J]. Brachytherapy, 2011, 10(4):306-312. DOI:10.1016/j.brachy.2010.08.011.
[17] Baker C, Dini SA, Kudrimoti M, et al. Dosimetric evaluation of a newly designed low dose rate brachytherapy applicator for treatment of cervical cancer with extension into the lower vagina[J]. J Appl Clin Med Phys, 2007, 8(2):37-46. DOI:10.1120/jacmp.v8i2.2400.
[18] Wazer DE, Lowther D, Boyle T, et al. Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 50(1):107-111. DOI:10.1016/s0360-3016(00)01541-8.
[19] Vikram B, Deore S, Beitler JJ, et al. The relationship between dose heterogeneity ("hot" spots) and complications following high-dose rate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 1999, 43(5):983-987.
[20] Wachter-Gerstner N, Wachter S, Reinstadler E, et al. The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer:results of a prospective comparative trial[J]. Radiother Oncol, 2003, 68(1):51-59. DOI:10.1016/s0167-8140(03)00083-5.